CYP19A1 and breast cancer: Clinically, patients with ER + BC are treated with endocrine therapies that either block the production of E using aromatase inhibitors (AI), or that antagonise E activity by competitively binding the ER, such as tamoxifen, a selective ER modulator (SERM)2.